Increased activation of protein C, but lower plasma levels of free, activated protein C in uraemic patients: Relationship with systemic inflammation and haemostatic activation

British Journal of Haematology

Volumn 113, Issue 4, 2001, Pages 905-910

  Mezzano, Diego ^a,e   España, Francisco ^b   Panes, Olga ^a   Medina, Piedad ^b   Pais, Edgar ^c   Marshall, Guillermo ^a   Tagle, Rodrigo ^c   Downey, Patricio ^c   Caceres, Soledad ^a   González, Fernando ^d   Quiroga, Teresa ^a   Pereira, Jaime ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c Department of Nephrology ^*  (Chile)

^d UNIVERSITY OF CHILE   (Chile)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Activated protein C; Haemostasis activation; Systemic inflammation; Uraemia

Indexed keywords

ACTIVATED PROTEIN C; ACUTE PHASE PROTEIN; ALPHA 1 ANTITRYPSIN; ANTIPLASMIN; ANTITHROMBIN; C REACTIVE PROTEIN; CREATININE; CYTOKINE; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; INTERLEUKIN 8; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 3; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOSIS; UREMIA;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; ANTITHROMBINS; C-REACTIVE PROTEIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; INTERLEUKIN-8; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLASMIN; PROTEIN C; STATISTICS, NONPARAMETRIC; THROMBIN; TUMOR NECROSIS FACTOR-ALPHA; VON WILLEBRAND FACTOR;

EID: 0034932458     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02848.x     Document Type: Article

References (38)

1. Activation of protein C pathway in acute sepsis
2. Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure
3. Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries
4. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages
5. Endothelial protein C receptor
6. Determination of antigen and functional protein C inhibitor and its complexes with activated protein C in plasma by ELISA's
7. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombosis
8. In vivo and in vitro complexes of activated protein C with two inhibitors in baboons
9. Quantification of circulating activated protein C in human plasma by immunoassays - Enzyme levels are proportional to total protein C levels
10. Plasma D dimer: A useful marker of fibrin breakdown in renal failure
11. Direct detection of activated protein C in blood from human subjects
12. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis
13. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates
14. Inhibition and complexation of activated protein C by two major inhibitors in plasma
15. Functional and immunological determination of protein C by immunosorbent assays
16. Plasma thrombomodulin levels are dependent on renal function
17. A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model
18. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: Relationship with dyslipidemia, inflammation and factor VII genotype
19. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications
20. Hemostatic disorder of uremia: The platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis
21. Endothelial cell markers in chronic uremia: Relationship with hemostatic defects and severity of renal failure
22. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure
23. Vegetarians and cardiovascular risk factors: Hemostasis, inflammatory markers and plasma homocysteine
24. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation
25. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment
26. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects
27. Plasma levels of IL-1ß, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients
28. Fibrinolytic and inflammatory markers for arterial occlusion: The evolving epidemiology of thrombosis and hemostasis
29. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis
30. Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure
31. Increased activated protein C: Protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis
32. Protein C prevents the coagulopathic and lethal effects of E coli infusion in the baboon
33. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment
34. Epidemiological evidence for inflammation in cardiovascular disease
35. Activation of coagulation after administration of tumor necrosis factor to normal subjects
36. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients
37. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C